RETATRUTIDE - 46 ads

Tuesday, July 29, 2025

Quantity : 10mg*10via - Price : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday, July 29, 2025

Quantity : 5mg*10vial - Price : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Saturday, July 26, 2025

Quantity : 5mg*10vial - Price : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday, July 25, 2025

Quantity : 60mg*10via - Price : USD 650

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday, July 25, 2025

Quantity : 50mg*10via - Price : USD 550

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday, July 25, 2025

Quantity : 40mg*10via - Price : USD 450

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday, July 25, 2025

Quantity : 30mg*10via - Price : USD 360

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday, July 25, 2025

Quantity : 20mg*10via - Price : USD 300

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday, July 25, 2025

Quantity : 15mg*10via - Price : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday, July 25, 2025

Quantity : 10mg*10via - Price : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday, July 25, 2025

Quantity : 5mg*10vial - Price : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday, July 09, 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday, July 04, 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday, June 25, 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday, April 22, 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday, April 16, 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...